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ABSTRACT
Background    Acute promyelocytic leukemia (APL) is 
a disease characterized by expression of promyelocytic 
leukemia–retinoic acid receptor α (PML-RARα) chi-
meric mRNA. Although APL is curable, early death due 
to hemorrhage is a major problem. Here, we report the 
development of a simple and rapid diagnostic method for 
APL based on reverse transcription loop-mediated iso-
thermal amplification (RT-LAMP).
Methods    An RT-LAMP primer set was designed to 
detect three types of PML-RARα mRNA in a single 
reaction. Serial dilutions of plasmid DNA containing 
bcr1, bcr2, or bcr3 PML-RARα sequences and RNA 
extracted from bone marrow aspirates of 6 patients with 
APL were used to compare the results of RT-LAMP and 
nested PCR assays.
Results    Plasmid DNA was amplified by RT-LAMP, 
for which the reaction time was > 4 h shorter and the 
lower detection limit was higher than for nested RT-
PCR. Six of 7 samples tested positive by both methods. 
Conclusion    We developed an RT-LAMP assay for 
simple and rapid PML-RARα mRNA detection that may 
be clinically useful for point-of-care testing and APL 
diagnosis.
Key words    acute promyelocytic leukemia; polymerase 
chain reaction; promyelocytic leukemia–retinoic acid 
receptor α; reverse transcription loop-mediated isother-
mal amplification; t(15;17) chromosome translocation
Loop-mediated isothermal amplification (LAMP) is an 
established nucleic acid amplification method that re-
quires a set of 4 specially designed, highly specific inner 
and outer primers.1 Additional loop primers can further 
accelerate the reaction.2 The LAMP product is detected 
by turbidity arising from magnesium pyrophosphate 
formed during the reaction.3 This method is very rapid 
and directly amplifies the target region from an RNA 
sample, and has been used to detect various pathogens, 
including bacteria and viruses.4 In addition, LAMP has 
now been developed as commercial kits, some of which 
have been adopted as officially recommended methods 
for routine pathogen examination and surveillance in 
Japan.5 However, there have been few applications of 
LAMP to the field of hematological malignancy, al-
though one notable exception is the detection of Wilms’ 
tumor-1 gene mRNA.6
 Acute promyelocytic leukemia (APL) is a distinct 
subtype of acute myeloid leukemia (AML) accounting 
for approximately 10% of cases. APL is cytogenetical-
ly characterized by balanced reciprocal translocation 
between chromosomes 15 and 17, which results in the 
fusion of the promyelocytic leukemia (PML) and retino-
ic acid receptor α (RARα) genes.7 The PML-RARα chi-
meric gene is detected in nearly all APL patients and is 
used as a marker for clinical diagnosis. In addition, the 
mRNA is detected by reverse transcription polymerase 
chain reaction (RT-PCR) and/or real time RT-PCR for 
minimal residual disease monitoring of APL.8–10 Three 
different types of PML-RARα mRNA exist owing to 
different breakpoints in the PML gene, although these 
do not result in different treatment outcomes: the long-, 
variable-, and short-form types are derived from break-
points at bcr1 (intron 5), bcr2 (exon 6), and bcr3 (intron 
3), respectively, and occur at relative frequencies of 55%, 
5%, and 40%, respectively.11
 APL is the most curable form of AML because of 
an established molecular targeted therapy combining all-
trans retinoic acid (ATRA) and arsenic trioxide.12 Before 
starting the treatment, it is necessary to verify that the 
patient has the PML-RARα fusion gene.13 However, ear-
ly death—mostly due to severe hemorrhage—remains 
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the main cause of APL treatment failure according to 
recent population-based studies carried out in developed 
countries.14 Some reports recommend early and timely 
initiation of ATRA and provision of aggressive sup-
portive care at the first suspicion of the disease, without 
awaiting molecular confirmation, in order to reduce 
hemorrhagic deaths in APL.14 An improved PML-RARα 
mRNA detection test is also needed.
 We report here the development of a simple reverse 
transcription loop-mediated isothermal amplification 
(RT-LAMP) method for rapid PML-RARα mRNA de-
tection. The advantages of this method with respect to 
RT-PCR are also discussed.
MATERIALS AND METHODS
Samples
Three different plasmids—containing bcr1, bcr2, and 
bcr3 PML-RARα mRNA sequences—were purchased 
from Eurofins Genomics (Louisville, KY) for use as 
positive controls. Vector plasmid was pTAKN-2 and 
chimeric sequences were made of sequences derived 
from the Genbank sequence database (Accession num-
bers are M73778, NM_000964, and AB067754). IVS-
0035 RNA (Invivoscribe Technologies, San Diego, CA) 
was used as a negative control. Clinical samples used in 
this study were archived specimens from APL patients 
diagnosed by detection of APL cells and PML-RARα 
mRNA by nested RT-PCR at our hospital. RNA was 
extracted from patient bone marrow aspirates using the 
RNeasy Plus Mini kit (Qiagen, Valencia, CA) accord-
ing to the manufacturer’s instructions; these were used 
for diagnosis, and then frozen at −80 °C until the study. 
RNA concentrations were measured and 260/280 nm 
absorbance ratios were determined with a Nanodrop 
2000 spectrophotometer (Thermo Fisher Scientific, 
Waltham, MA) prior to RT-LAMP and nested RT-PCR 
assays. The study protocol was approved by the Tottori 
University Hospital ethics committee (number 2326).
Primer design
Primer sets for detection of PML-RARα mRNA by RT-
LAMP (Table 1) were designed using PrimerExplorer 
ver. 4 software (Eiken Chemical, Tokyo, Japan). The 
primer sets were modified to detect the three types of 
PML-RARα mRNA in a single tube—i.e., bcr1 and bcr2 
were amplified with the same primer sets and an addi-
tional set consisting of FIP, F3, and LF were included in 
one reaction to amplify bcr3 (Fig 1).
RT-LAMP
The RT-LAMP assay was carried out using the Loopa-
mp RNA Amplification kit (Eiken Chemical, Tokyo, 
Japan) under the following conditions: 1 μL sample (RNA 
or DNA) was mixed with 20 pmol each of FIP and BIP 
primers, 10 pmol each of LF and LB primers, 2.5 pmol 
each of F3 and B3 primers, 1 μL Enzyme Mix, and 12.5 
μL of 2 × Reaction Mix, with distilled water added to 
obtain a final volume of 25 μL. For real-time turbidity 
monitoring, the reaction mixture was incubated at 68 °C 
for 60 min in an RT-160C Loopamp Realtime Turbidi-
meter (Eiken Chemical). The specificity of LAMP was 
confirmed by restriction enzyme digestion using DdeI 
(Takara Bio, Otsu, Japan) under the following condi-
tions: 5 μL LAMP product was mixed with 2 μL of 10 
× K buffer (Takara Bio), 1 μL DdeI, with distilled water 
added to obtain a final volume of 20 μL, followed by 
incubation at 37 °C for 120 min. DdeI was inactivated 
at 70 °C for 15 min and the digestion products (10-μL 
aliquots) were mixed with loading buffer (Nippon Gene, 
Toyama, Japan) and separated by 1.5% agarose gel 
electrophoresis (100 V, 35 min) with 0.005% ethidium 
bromide using a Mupid mini gel electrophoresis system 
(Advance, Tokyo, Japan), with 5 μL Gene Ladder 100 
(Nippon Gene) used as a molecular size marker.
Nested RT-PCR
The RT reaction was carried out using1 μL RNA sample 
and the ThermoScript RT-PCR system (Thermo Fisher 
Scientific) according to the manufacturers’ protocol. 
Three types of PML-RARα mRNA were detected using 
two forward primer sets designed according to published 
sequences.10 Specifically, bcr1 and bcr2 types were 
amplified with the same primer set. The PCR reaction 
mixture was prepared using AmpliTaq Gold with 10 × 
PCR Gold Buffer and MgCl2 (Thermo Fisher Scientific) 
and the GeneAmp dNTP mix (Thermo Fisher Scientific) 
under the following conditions: 1 μL plasmid DNA, 2 
μL cDNA, or 1 μL first PCR product was mixed with 
Table 1. Primers for detection of PML-RARα mRNA 
by RT-LAMP
Primers Sequence (5’ → 3’)
bcr1,2 FIP TCCCCTCCTCAGACTCCATCTTGAAGAGGAAGTGCAGCCAGA
bcr1,2 F3 CTCCAATACAACGACAGCC
bcr3 FIP TTGAACTCGTCGAAGCCATCGGCTGGACATGCACGGTT
bcr3 F3 AAGTGCTACGCCTCGGA
BIP TGAGACCCAGAGCAGCAGTTGTAGATGCGGGGTAGA
B3 TGACAGACAAAGCAAGGC
bcr1,2 LF GATGACCTTCCTGGGGCA
bcr3 LF ACGGCAGCTTGCAGGCT
LB TGAAGAGATAGTGCCCAGCCCT
PML-RARα, promyelocytic leukemia–retinoic acid receptor α; 
RT-LAMP, reverse transcription loop-mediated isothermal ampli-
fication.
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Fig. 1. Schematic representation of primer design for detection of PML-RARα mRNA by RT-LAMP and cutting sites of DdeI restriction 
enzyme assay. Exon numbers of the PML gene (dark) and the RARα gene (light) are shown. PML, promyelocytic leukemia; RARα, retino-
ic acid receptor α; RT-LAMP, reverse transcription loop-mediated isothermal amplifi cation.
2.5 μL 10 × PCR Gold buffer, 2.25 nmol MgCl2 solu-
tion, 500 pmol dNTP mix, 0.2 μL AmpliTaq Gold DNA 
polymerase, and 0.25 pmol each forward and reverse 
primers, with distilled water added to obtain a final 
volume of 25 μL. The forward primers were as follows: 
5’-AGTCAGTGCCCGGGGCACAC-3’ for bcr1 and 
bcr2 and 5’-AGCTGCTGGAGGCTGTGGACG-3’ for 
bcr3 in the fi rst PCR; and 5’-AGTGTACGCCTTCTC-
CATCAAAG-3’ for bcr1 and bcr2 and 5’-TGTGCTG-
CAGCGACTCCGCA-3’ for bcr3 in the second PCR. 
The reverse primers were as follows: 5’-AGGGCTGG-
GCACTATCTCTTC-3’ for bcr1, bcr2, and bcr3 in the 
first PCR; and 5’-CAGAACTGCTGCTCTGGGTCT-
CAAT-3’ for bcr1, bcr2, and bcr3 in the second PCR. 
Reaction conditions on the MultiGene Mini Personal 
Thermal Cycler (Labnet International, Edison, NJ) were 
as follows: 94 °C for 5 min; 35 cycles at 94 °C for 30 s, 
62 °C for 1 min, and 72 °C for 1 min; and 72 °C for 7 
min. The nested PCR products (10-μL aliquots) were 
mixed with loading buffer and separated along with 5 
μL of molecular size marker by 1.5% agarose gel elec-
trophoresis (100 V, 35 min) with 0.005% ethidium bro-
mide.
RNA integrity number (RIN) analysis
The quality of clinical RNA samples (expect for S-4, 
for which the amount was insuffi cient) was evaluated by 
RIN as previously described15 on an Agilent 2100 Bio-
analyzer (Agilent Technologies, Santa Clara, CA).
RESULTS
Specifi city of amplifi cation by RT-LAMP
We performed the RT-LAMP assay with two concen-
trations of plasmid DNA followed by DdeI restriction 
enzyme analysis. All plasmid DNAs were detected by 
RT-LAMP in 60 min (data not shown, Fig. 2A) and 
yielded the expected products after digestion with DdeI 
(Fig. 3), which differed for each breakpoint. Non-spe-
cifi c amplifi cation products obtained after 60 min from 
PML-RARα-negative RNA were not digestible by DdeI 
(Fig. 3).
Sensitivity of the RT-LAMP assay
The lower detection limit of the RT-LAMP assay was 
determined using10-fold serial dilutions of bcr1, bcr2, 
and bcr3 plasmid DNA; the result was compared to that 
obtained by nested RT-PCR. RT-LAMP was able to de-
tect 880, 78, and 800 copies/tube of bcr1, bcr2, and bcr3 
plasmid, respectively (Fig. 2A), as compared to 0.88, 
7.8, and 80 copies/tube, respectively, by nested RT-PCR 
(Figs. 4A–C). The specifi city of all RT-LAMP products 
was confi rmed by DdeI restriction enzyme digestion.
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Fig. 2. Detection of PML-RARα in plasmid DNA and clinical RNA samples by RT-LAMP. (A) Ten-fold serial dilutions of bcr1, bcr2, and 
bcr3 plasmid DNAs were used as template; the starting amounts were 8.8, 7.8, and 8.0 × 108 copies/tube, respectively. DF of the indicated 
plasmid DNA is shown as a logarithmic value. (B) Clinical samples from APL patients (S-1 through -7) were analyzed by RT-LAMP. 
IVS-0035 RNA and distilled water were used as negative controls. A 100-fold dilution of corresponding plasmid DNAs served as a pos-
itive control. The amplification reaction was carried out at 68 °C for indicated times. APL, acute promyelocytic leukemia; DF, dilution 
factor; PML-RARα, promyelocytic leukemia–retinoic acid receptor α; RT-LAMP, reverse transcription loop-mediated isothermal ampli-
fication. 
Fig. 3. DdeI restriction enzyme digestion 
of RT-LAMP products. Products of bcr1, 
bcr2, and bcr3 plasmid DNA amplification 
were incubated with (+) or without (−) 
DdeI at 37 °C for 120 min, followed by 
deactivation at 70 °C for 15 min and sepa-
ration by 1.5% agarose gel electrophoresis 
(100 V, 35 min). The amounts of bcr1, 
bcr2 and bcr3 plasmid DNAs were 8.8, 
7.8, and 8.0 × 106 copies/tube, respectively. 
The expected sizes of digested RT-LAMP 
products are the followings: 468 bp, about 
234 bp (stem and loop structure) and 83 bp 
for bcr1; 232 bp, about 116 bp (stem and 
loop structure) and 83 bp for bcr2; and 139 
bp and 121 bp (merged in Figure) for bcr3. 
DW, distilled water (negative control); M, 
100-bp ladder size marker; neg RNA, IVS-
0035 RNA (negative control); RT-LAMP, 
reverse transcription loop-mediated iso-
thermal amplification.
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Fig. 4. Nested RT-PCR amplification 
using 10-fold serial dilutions of plas-
mid DNA. Plasmid DNAs contain-
ing (A) bcr1, (B) bcr2, and (C) bcr3 
sequences (starting amounts: 8.8 × 
108, 7.8 × 108, and 8.0 × 108 copies/
tube, respectively) were diluted by the 
indicated DF and amplified by nested 
RT-PCR. Amplification products 
were separated by 1.5% agarose gel 
electrophoresis (100 V, 35 min). DF, 
dilution factor; DW, distilled water; M, 
100-bp ladder size marker; RT-PCR, 
reverse transcription polymerase 
chain reaction.
Table 2. Comparison between RT-LAMP and nested RT-PCR using clinical samples
Sample number Breakpoint type RNA concentration(ng/μL)
Absorbance ratio
(260/280 mm) RIN value RT-LAMP
Nested
RT-PCR
S-1 bcr1 250.8 2.04 9.60 + +
S-2 bcr1 535.0 2.04 10 + +
S-3 bcr1 361.9 1.96 NM – –
S-4 bcr1 1141.0 2.06 NA + +
S-5 bcr3 389.8 2.06 9.50 + +
S-6 bcr3 309.2 2.05 9.90 + +
S-7 bcr3 59.9 2.04 8.50 + +
NA, not available; NM, not measured due to pattern deformation; RIN, RNA integrity number; RT-LAMP, reverse transcription loop-me-
diated isothermal amplification; RT-PCR, reverse transcription polymerase chain reaction; Samples 5 and 6 were derived from the same 
patient: S-5, at the initial visit and S-6, at the time of relapse. 
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Fig. 5. Confirmation of bcr1 and bcr3 of clinical samples after RT-LAMP assay. The RT-LAMP products of clinical sample RNAs of 
S-1 (A) and S-5 (B) were incubated with (+) or without (−) DdeI at 37 °C for 120 min, followed by deactivation at 70 °C for 15 min and 
separation by 1.5% agarose gel electrophoresis (100 V, 35 min). M, 100-bp ladder size marker; RT-LAMP, reverse transcription loop-me-
diated isothermal amplification.
RT-LAMP of clinical samples
Clinical samples were analyzed by RT-LAMP and nest-
ed RT-PCR; these included four bcr1- and three bcr3-
type PML-RARα RNAs. The plasmid DNAs were used 
as positive controls, and IVS-0035 RNA and distilled 
water were used as negative controls. Three bcr1- and 
three bcr3-type RNAs were detected by RT-LAMP (Fig. 
2B); the products were confirmed by DdeI restriction en-
zyme digestion (Fig. 5), and the results were the same as 
those obtained by nested RT-PCR (Table 2). One sample 
yielded no product with both assays; this RNA had been 
stored for the longest period (about 9 years) and was 
likely degraded, as indicated by RIN analysis of RNA 
quality.15, 16
DISCUSSION
Each type of PML-RARα sequence was specifically 
amplified by RT-LAMP; moreover, each PML-RARα 
breakpoints as well as non-specific amplification could 
be distinguished by digesting the products with DdeI. 
The sensitivity of the RT-LAMP assay was inferior to 
that of nested RT-PCR by 10 fold for bcr2 and bcr3 and 
by 1000 fold for bcr1. Some RT-LAMP assays have 
higher sensitivity than nested RT-PCR,17–20 while others 
have lower sensitivity.21, 22 This depends on the primers 
used, which determine the amplification efficiency and 
has a significant effect on the sensitivity of gene ampli-
fication. In this study, we selected 5 primer sets from 
more than 1000 candidates listed by PrimerExplorer 
ver. 4. It is virtually impossible to test all candidates, al-
though a primer set with better amplification efficiency 
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may exist. 
 RT-LAMP and nested RT-PCR yielded similar 
results in the analysis of clinical samples. This sug-
gests that RT-LAMP has clinical utility as a diagnostic 
test, especially at initial presentation when a sufficient 
amount of PML-RARα mRNA is available.
 The nested RT-PCR assay requires about 6 h from 
RNA extraction to target mRNA detection. In contrast, 
PML-RARα mRNA was amplified in 30 min by RT-
LAMP, and is therefore more useful for early diagnosis 
and determination of an appropriate intervention. In ad-
dition, the amount of sample that is lost with RT-LAMP 
is minimal because the extracted RNA is used directly 
in the amplification reaction even in one tube. This sim-
plifies the procedure, thereby reducing the labor and cost 
of laboratory testing. 
 Spinelli et al. recently reported another assay using 
RT-LAMP to detect PML-RARα chimeric gene.23 Us-
ing fluorescence, the assay appeared to be more rapid 
and sensitive than our assay. However, the detection of 
fluorescence requires a dedicated devise and their assay 
needs 2 reaction tubes to detect 3 PML-RARα mR-
NAs. In addition, primer sequences were not described. 
Therefore, our assay has advantages of simple procedure 
and low cost, and could readily be applied in developing 
countries. Such simplicity can lead to the development 
of an automated system that can be used for point-of-
care testing and diagnosis of APL.
 In conclusion, we developed an RT-LAMP assay 
for detection of PML-RARα mRNA in clinical samples 
from APL patients. This assay is more simple and rapid 
than nested RT-PCR, and can contribute to early diagno-
sis of APL. 
 
Acknowledgments: The authors would like to thank Mr. Yasuharu 
Sasaki for technical advice and Editage (www.editage.jp) for En-
glish editing. 
     This study was supported by a grant from Seeds Research Proj-
ect at Tottori University Hospital.
The authors declare no conflict of interest.  
REFERENCES
  1 Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe 
K, Amino N, et al. Loop-mediated isothermal amplification 
of DNA. Nucleic Acids Res. 2000;28:E63. PMID: 10871386.
  2 Nagamine K, Hase T, Notomi T. Accelerated reaction by 
loop-mediated isothermal amplification using loop primers. 
Mol Cell Probes. 2002;16:223-9. PMID: 12144774.
  3 Mori Y, Nagamine K, Tomita N, Notomi T. Detection of 
loop-mediated isothermal amplification reaction by turbidity 
derived from magnesium pyrophosphate formation. Biochem 
Biophys Res Commun. 2001;289:150-4. PMID: 11708792.
  4 Dhama K, Karthik K, Chakraborty S, Tiwari R, Kapoor S, 
Kumar A, et al. Loop-mediated isothermal amplification of 
DNA (LAMP): a new diagnostic tool lights the world of diag-
nosis of animal and human pathogens: a review. Pak JBiol Sci. 
2014;17:151-66. PMID: 24783797.
  5 Mori Y, Notomi T. Loop-mediated isothermal amplification 
(LAMP): a rapid, accurate, and cost-effective diagnostic meth-
od for infectious diseases. J Infect Chemother. 2009;15:62-9. 
PMID: 19396514.
  6 Morishita S, Tani H, Kurata S, Nakamura K, Tsuneda S, 
Sekiguchi Y, et al. Real-time reverse transcription loop-medi-
ated isothermal amplification for rapid and simple quantifica-
tion of WT1 mRNA. Clin Biochem. 2009;42:515-20. PMID: 
19297684.
  7 Kakizuka A, Miller WH, Umesono K, Warrell RP, 
Frankel SR, Murty VV, et al. Chromosomal translocation 
t(15;17) in human acute promyelocytic leukemia fuses RAR 
alpha with a novel putative transcription factor, PML. Cell. 
1991;66:663-74. PMID: 1652368.
  8 Miller WH, Kakizuka A, Frankel SR, Warrell RP, 
DeBlasio A, Levine K, et al. Reverse transcription polymerase 
chain reaction for the rearranged retinoic acid receptor alpha 
clarifies diagnosis and detects minimal residual disease in 
acute promyelocytic leukemia. Proc Natl Acad Sci USA. 
1992;89:2694-8. PMID: 1372989.
  9 van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, 
Rossi V, Saglio G, et al. Standardized RT-PCR analysis of 
fusion gene transcripts from chromosome aberrations in acute 
leukemia for detection of minimal residual disease. Report of 
the BIOMED-1 Concerted Action: investigation of minimal 
residual disease in acute leukemia. Leukemia. 1999;13:1901-
28. PMID: 10602411.
10 Tobal K, Liu Yin JA. RT-PCR method with increased sen-
sitivity shows persistence of PML-RARA fusion transcripts 
in patients in long-term remission of APL. Leukemia. 
1998;12:1349-54. PMID: 9737682.
11 Gallagher RE, Willman CL, Slack JL, Andersen JW, Li YP, 
Viswanatha D, et al. Association of PML-RAR alpha fusion 
mRNA type with pretreatment hematologic characteristics but 
not treatment outcome in acute promyelocytic leukemia: an 
intergroup molecular study. Blood. 1997;90:1656-63. PMID: 
9269786.
12 Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, 
Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute 
promyelocytic leukemia. New Engl JMed. 2013;369:111-21. 
PMID: 23841729.
13 Wang ZY, Chen Z. Acute promyelocytic leukemia: from high-
ly fatal to highly curable. Blood. 2008;111:2505-15. PMID: 
18299451.
14 Breccia M, Coco FL. Thrombo-hemorrhagic deaths in acute 
promyelocytic leukemia. Thromb Res. 2014;133:S112-S6. 
PMID: 24862130.
15 Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, 
Gassmann M, et al. The RIN: an RNA integrity number for 
assigning integrity values to RNA measurements. BMC Mol 
Biol. 2006;7:3. PMID: 16448564.
16 Imbeaud S, Graudens E, Boulanger V, Barlet X, Zaborski P, 
Eveno E, et al. Towards standardization of RNA quality as-
sessment using user-independent classifiers of microcapillary 
electrophoresis traces. NucleicAcids Res. 2005;33:e56. PMID: 
15800207.
17 Lee S, Kim JH, Choi JY, Jang WC. Loop-mediated isother-
mal amplification assay to rapidly detect wheat streak mosaic 
virus in quarantined plants. Plant Pathol J. 2015;31:438-40. 
PMID: 26674930.
269
RT-LAMP for rapid detection of PML-RARα mRNA
18 Zhang Q, Liu S, Yang H, Zhu L, Wan X, Li X, et al. Reverse 
transcription loop-mediated isothermal amplification for rapid 
and quantitative assay of covert mortality nodavirus in shrimp. 
J Invertebr Pathol. 2015; Sep 9. doi: 10.1016/j.jip.2015.09.001. 
PMID: 26363123.
19 Liu DF, Liu CG, Tian J, Jiang YT, Zhang XZ, Chai HL, et al. 
Establishment of reverse transcription loop-mediated isother-
mal amplification for rapid detection and differentiation of ca-
nine distemper virus infected and vaccinated animals. Infect 
Genet Evol. 2015;32:102-6. PMID: 25769803.
20 A r un r ut N, Suebsing R, Withyachum na r n kul B, 
Kiatpathomchai W. Demonstration of a very inexpensive, 
turbidimetric, real-time, RT-LAMP detection platform using 
shrimp Laem-Singh virus (LSNV) as a model. PLoS ONE. 
2014;9:e108047. PMID: 25255231.
21 Hanaki K, Ike F, Hatakeyama R, Hirano N. Reverse transcrip-
tion-loop-mediated isothermal amplification for the detection 
of rodent coronaviruses. J Virol Methods. 2013;187:222-7. 
PMID: 23123121
22 Kiatpathomchai W, Jareonram W, Jitrapakdee S, Flegel TW. 
Rapid and sensitive detection of Taura syndrome virus by re-
verse transcription loop-mediated isothermal amplification. J 
Virol Methods. 2007;146:125-8. PMID: 17643501.
23 Spinelli O, Rambaldi A, Rigo F, Zanghì P, D’Agostini E, Ami-
carelli G, et al. Simple, rapid and accurate molecular diagnosis 
of acute promyelocytic leukemia by loop mediated amplifica-
tion technology. Oncoscience. 2015;2:50-8. PMID: 25815362.
